|
1
|
Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi
Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, et al:
Proteogenomic characterization of human colon and rectal cancer.
Nature. 513:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li B, Li C, Guo M, Shang S, Li X, Xie P,
Sun X, Yu J and Wang L: Predictive value of LDH kinetics in
bevacizumab treatment and survival of patients with advanced NSCLC.
Onco Targets Ther. 11:6287–6294. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gregorc V, Novello S, Lazzari C, Barni S,
Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, et
al: Predictive value of a proteomic signature in patients with
non-small-cell lung cancer treated with second-line erlotinib or
chemotherapy (PROSE): A biomarker-stratified, randomised phase 3
trial. Lancet Oncol. 15:713–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lazzari C, Spreafico A, Bachi A, Roder H,
Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG,
Sorlini C, et al: Changes in plasma mass-spectral profile in course
of treatment of non-small cell lung cancer patients with epidermal
growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol.
7:40–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garrisi VM, Bongarzone I, Mangia A,
Cremona M, De Bortoli M, Vaghi E, Galetta D, Pastorino U, Quaranta
M, Abbate I and Paradiso A: Characterization of a serum protein
pattern from NSCLC patients treated with Gefitinib. Clin Biochem.
44:936–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pitteri SJ, Amon LM, Busald Buson T, Zhang
Y, Johnson MM, Chin A, Kennedy J, Wong CH, Zhang Q, Wang H, et al:
Detection of elevated plasma levels of epidermal growth factor
receptor before breast cancer diagnosis among hormone therapy
users. Cancer Res. 70:8598–8606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung CH, Seeley EH, Roder H, Grigorieva
J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA,
Gilbert J, et al: Detection of tumor epidermal growth factor
receptor pathway dependence by serum mass spectrometry in cancer
patients. Cancer Epidemiol Biomarkers Prev. 19:358–365. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taguchi F, Solomon B, Gregorc V, Roder H,
Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V,
et al: Mass spectrometry to classify non-small-cell lung cancer
patients for clinical outcome after treatment with epidermal growth
factor receptor tyrosine kinase inhibitors: A multicohort
cross-institutional study. J Natl Cancer Inst. 99:838–846. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grossi F, Genova C, Rijavec E, Barletta G,
Biello F, Dal Bello MG, Meyer K, Roder J, Roder H and Grigorieva J:
Prognostic role of the VeriStrat test in first line patients with
non-small cell lung cancer treated with platinum-based
chemotherapy. Lung Cancer. 117:64–69. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fidler MJ, Fhied CL, Roder J, Basu S,
Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P and Borgia JA: The
serum-based VeriStrat® test is associated with
proinflammatory reactants and clinical outcome in non-small cell
lung cancer patients. BMC Cancer. 18:3102018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun W, Zhang X, Ding X, Li H, Geng M, Xie
Z, Wu H and Huang M: Lactate dehydrogenase B is associated with the
response to neoadjuvant chemotherapy in oral squamous cell
carcinoma. PLoS One. 10:e01259762015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferrer I, Quintanal-Villalonga Á,
Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S,
Paz-Ares L and Carnero A: MAP17 predicts sensitivity to
platinum-based therapy, EGFR inhibitors and the proteasome
inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res.
37:1952018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Zhang B, Yang YF, Jin J and Liu YH:
Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant
chemotherapy response in breast cancer: A meta-analysis. Medicine
(Baltimore). 97:e120562018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu KH, Levine DA, Zhang H, Chan DW, Zhang
Z and Snyder M: Predicting ovarian cancer patients' clinical
response to platinum-based chemotherapy by their tumor proteomic
signatures. J Proteome Res. 15:2455–2465. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chauvin A, Wang CS, Geha S, Garde-Granger
P, Mathieu AA, Lacasse V and Boisvert FM: The response to
neoadjuvant chemoradiotherapy with 5-fluorouracil in locally
advanced rectal cancer patients: A predictive proteomic signature.
Clin Proteomics. 15:162018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu J, Jiang H, Wu C, Jiang Y, Xiao L and
Tian Y: Overcoming cetuximab resistance in Ewing's sarcoma by
inhibiting lactate dehydrogenase-A. Mol Med Rep. 14:995–1001. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakurai T, Komeda Y, Nagai T, Kamata K,
Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N,
et al: Gankyrin contributes to tumorigenesis and chemoresistance in
sporadic colorectal cancer. Digestion. 4:1–9. 2018. View Article : Google Scholar
|
|
18
|
Kawazoe A, Shitara K, Fukuoka S, Kuboki Y,
Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, et al: A
retrospective observational study of clinicopathological features
of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with
metastatic colorectal cancer. BMC Cancer. 15:2582015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leto SM and Trusolino L: Primary and
acquired resistance to EGFR-targeted therapies in colorectal
cancer: Impact on future treatment strategies. J Mol Med (Berl).
92:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong R and Cunningham D: Using predictive
biomarkers to select patients with advanced colorectal cancer for
treatment with epidermal growth factor receptor antibodies. J Clin
Oncol. 26:5668–5670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khambata-Ford S, Garrett CR, Meropol NJ,
Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin
AK, et al: Expression of epiregulin and amphiregulin and K-ras
mutation status predict disease control in metastatic colorectal
cancer patients treated with cetuximab. J Clin Oncol. 25:3230–3237.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Price T, Kim TW, Li J, Cascinu S, Ruff P,
Suresh AS, Thomas A, Tjulandin S, Guan X and Peeters M: Final
results and outcomes by prior bevacizumab exposure, skin toxicity,
and hypomagnesaemia from ASPECCT: Randomized phase 3
non-inferiority study of panitumumab versus cetuximab in
chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Eur J Cancer. 68:51–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Molinari F, Felicioni L, Buscarino M, De
Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R,
Alabiso O, et al: Increased detection sensitivity for KRAS
mutations enhances the prediction of anti-EGFR monoclonal antibody
resistance in metastatic colorectal cancer. Clin Cancer Res.
17:4901–4914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sartore-Bianchi A, Moroni M, Veronese S,
Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S,
Colucci G, et al: Epidermal growth factor receptor gene copy number
and clinical outcome of metastatic colorectal cancer treated with
panitumumab. J Clin Oncol. 25:3238–3245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rankin A, Klempner SJ, Erlich R, Sun JX,
Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, et
al: Broad detection of alterations predicted to confer lack of
benefit from EGFR antibodies or sensitivity to targeted therapy in
advanced colorectal cancer. Oncologist. 21:1306–1314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pietrantonio F, Petrelli F, Coinu A, Di
Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi
I, Lonati V, et al: Predictive role of BRAF mutations in patients
with advanced colorectal cancer receiving cetuximab and
panitumumab: A meta-analysis. Eur J Cancer. 51:587–594. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rowland A, Dias MM, Wiese MD, Kichenadasse
G, McKinnon RA, Karapetis CS and Sorich MJ: Meta-analysis of BRAF
mutation as a predictive biomarker of benefit from anti-EGFR
monoclonal antibody therapy for RAS wild-type metastatic colorectal
cancer. Br J Cancer. 112:1888–1894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ashraf SQ, Nicholls AM, Wilding JL,
Ntouroupi TG, Mortensen NJ and Bodmer WF: Direct and immune
mediated antibody targeting of ERBB receptors in a colorectal
cancer cell-line panel. Proc Natl Acad Sci USA. 109:21046–21051.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Troiani T, Martinelli E, Napolitano S,
Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A,
Sforza V, Nappi A, et al: Increased TGF-α as a mechanism of
acquired resistance to the anti-EGFR inhibitor cetuximab through
EGFR-MET interaction and activation of MET signaling in colon
cancer cells. Clin Cancer Res. 19:6751–6765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou X, Chen R, Xie W, Ni Y, Liu J and
Huang G: Relationship between 18F-FDG accumulation and lactate
dehydrogenase A expression in lung adenocarcinomas. J Nucl Med.
55:1766–1771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP
and Huang G: Knockdown of lactate dehydrogenase A suppresses tumor
growth and metastasis of human hepatocellular carcinoma. FEBS J.
279:3898–3910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li C, Chen Y, Bai P, Wang J, Liu Z, Wang T
and Cai Q: LDHB may be a significant predictor of poor prognosis in
osteosarcoma. Am J Transl Res. 8:4831–4843. 2016.PubMed/NCBI
|
|
36
|
Chen R, Zhou X, Yu Z, Liu J and Huang G:
Low expression of LDHB correlates with unfavorable survival in
hepatocellular carcinoma: Strobe-compliant article. Medicine
(Baltimore). 94:e15832015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui J, Quan M, Jiang W, Hu H, Jiao F, Li
N, Jin Z and Wang L, Wang Y and Wang L: Suppressed expression of
LDHB promotes pancreatic cancer progression via inducing glycolytic
phenotype. Med Oncol. 32:1432015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McCleland ML, Adler AS, Shang Y, Hunsaker
T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, et
al: An integrated genomic screen identifies LDHB as an essential
gene for triple-negative breast cancer. Cancer Res. 72:5812–5823.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leiblich A, Cross SS, Catto JW, Phillips
JT, Leung HY, Hamdy FC and Rehman I: Lactate dehydrogenase-B is
silenced by promoter hypermethylation in human prostate cancer.
Oncogene. 25:2953–2960. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maekawa M, Taniguchi T, Ishikawa J,
Sugimura H, Sugano K and Kanno T: Promoter hypermethylation in
cancer silences LDHB, eliminating lactate dehydrogenase isoenzymes
1–4. Clin Chem. 49:1518–1520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
McCleland ML, Adler AS, Deming L, Cosino
E, Lee L, Blackwood EM, Solon M, Tao J, Li L, Shames D, et al:
Lactate dehydrogenase B is required for the growth of
KRAS-dependent lung adenocarcinomas. Clin Cancer Res. 19:773–784.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koh YW, Lee SJ and Park SY: Prognostic
significance of lactate dehydrogenase B according to histologic
type of non-small-cell lung cancer and its association with serum
lactate dehydrogenase. Pathol Res Pract. 213:1134–1138. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dennison JB, Molina JR, Mitra S,
González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez
HL, Arteaga CL, et al: Lactate dehydrogenase B: A metabolic marker
of response to neoadjuvant chemotherapy in breast cancer. Clin
Cancer Res. 19:3703–3713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hirschhaeuser F, Sattler UG and
Mueller-Klieser W: Lactate: A metabolic key player in cancer.
Cancer Res. 71:6921–6925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bhattacharya B, Mohd Omar MF and Soong R:
The Warburg effect and drug resistance. Br J Pharmacol.
173:970–979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bhattacharya B, Low SH, Soh C, Kamal
Mustapa N, Beloueche-Babari M, Koh KX, Loh J and Soong R: Increased
drug resistance is associated with reduced glucose levels and an
enhanced glycolysis phenotype. Br J Pharmacol. 171:3255–3267. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hwang JH, Kim JY, Cha MR, Ryoo IJ, Choo
SJ, Cho SM, Tsukumo Y, Tomida A, Shin-Ya K, Hwang YI, et al:
Etoposide-resistant HT-29 human colon carcinoma cells during
glucose deprivation are sensitive to piericidin A, a GRP78
down-regulator. J Cell Physiol. 215:243–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jacobson C, Kopp N, Layer JV, Redd RA,
Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL,
Christodoulou A, et al: HSP90 inhibition overcomes ibrutinib
resistance in mantle cell lymphoma. Blood. 128:2517–2526. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Flandrin P, Guyotat D, Duval A, Cornillon
J, Tavernier E, Nadal N and Campos L: Significance of heat-shock
protein (HSP) 90 expression in acute myeloid leukemia cells. Cell
Stress Chaperones. 13:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sain N, Krishnan B, Ormerod MG, De Rienzo
A, Liu WM, Kaye SB, Workman P and Jackman AL: Potentiation of
paclitaxel activity by the HSP90 inhibitor
17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma
cell lines with high levels of activated AKT. Mol Cancer Ther.
5:1197–1208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lu H, Li X, Luo Z, Liu J and Fan Z:
Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated
LDH-A. Mol Cancer Ther. 12:2187–2199. 2013. View Article : Google Scholar : PubMed/NCBI
|
